The association of high pretreatment frequency of CD103+CD8+ and CD4+ T cells with major pathological response to therapy suggests that responding patients are likely to have an antecedent, nascent, albeit ineffective, anti-tumor immune response. The gene discussed is CD8A; the disease is neoplasm.